References
- Faich G. A., Dreis M., Tomita D. National adverse drug reaction surveillance: 1986. Arch. Intern. Med. 1988; 148: 785
- Faich G. A., Lawson D. H., Tilson H. H., et al. Clinical trials-are not enough: Drug development and pharmacy epidemiology. J. Clin. Res. Drug Dev. 1987; 1: 75
- Wardell W. M., Tsianco M. C., Anavekar S. N., et al. Postmarketing surveillance of new drugs: I. Review of objectives and methodology. J. Clin. Pharmacol. 1979; 19: 85
- Faich G. A. Adverse drug reaction monitoring. N. Engl. J. Med. 1986; 314: 1589
- Rossi A. C., Bosco L., Faich G. A., et al. The importance of adverse drug reaction reporting by physicians: Suprofen and the flank pain syndrome. JAMA 1988; 259: 1203
- Edalvitch S. A. Postmarketing surveillance methodologies. Drug Intell. Clin. Pharm. 1987; 21: 741
- Venning G. R. Identification of adverse drug reactions to new drugs: II (Continued). How were 18 important adverse drug reactions discovered and with what delays?. Br. Med. J. 1983; 286: 365
- Rossi A. C., Knapp D. E., Anello C., et al. Discovery of adverse drug reactions: A comparison of selected phase IV studies with spontaneous reporting methods. JAMA 1983; 249: 2226
- Griffin J. P., Weber J. C. P. Voluntary systems of adverse reaction reporting: Part II, Adverse Drug React. Acute Poisoning Rev. 1986; 1: 23
- Rogers A. S., Israel E., Smith C., et al. Physician knowledge, attitudes, and behaviour related to reporting adverse drug events. Arch. Intern. Med 1988; 148: 1596
- Drug Monitoring, F. H. Gross, W. H.W. Inman. London Academic Press, London 1977